2023 World Conference on Lung Cancer (Posters)-EP06.05. Histopathologic Changes of the Perioperative Pirfenidone Therapy in Lung Cancer with Idiopathic Pulmonary Fibrosis

EP06.05. Histopathologic Changes of the Perioperative Pirfenidone Therapy in Lung Cancer with Idiopathic Pulmonary Fibrosis - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the histopathologic changes associated with perioperative pirfenidone therapy in lung cancer patients with idiopathic pulmonary fibrosis (IPF). The antifibrotic agent, pirfenidone (PFD), has been shown to slow the progression of IPF and reduce mortality, but its effects on histological lung specimens are still unclear. <br /><br />The study analyzed 34 patients with IPF-complicated lung cancer who underwent surgery. The histopathological evaluation of inflammatory reaction and fibrosis was assessed using a severity scoring system. The patients were divided into two groups: those who received perioperative PFD therapy and those who did not. The study found that there was no significant difference in the inflammatory reaction between the two groups. However, in the lower lobectomy or lower segmentectomy cohort, there was a significant difference in the total inflammatory reaction score, with the PFD group experiencing a greater reduction in fibrosis compared to the control group.<br /><br />The findings suggest that perioperative PFD administration may prevent the progression of fibrosis by suppressing the activity of immune cells, particularly in the lower lobes. This is important because IPF is a progressive diffuse pulmonary disease that can lead to lung cancer complications and has a high mortality rate. The study provides insights into the potential benefits of PFD therapy in lung cancer patients with IPF, emphasizing the importance of considering this treatment option in the perioperative setting to potentially improve outcomes.

Asset Subtitle

Hodaka Oeda

Meta Tag

Speaker Hodaka Oeda

Topic Pathology & Biomarkers

Keywords

pirfenidone therapy

lung cancer patients

idiopathic pulmonary fibrosis

histological lung specimens

inflammatory reaction

fibrosis

lower lobectomy

lower segmentectomy

PFD group

immune cells